Inclusion Criteria:  New patient in the MD Anderson Cancer Center Nellie B. Connally Breast Center or Houston Area Locations (HALs) (presenting to the surgery clinic, medical oncology clinic, or multiteam clinic) Women 18 years and older treated at MD Anderson Cancer Center between 1/1/2019 and 12/31/2021 Diagnosis of triple negative invasive breast cancer on percutaneous needle biopsy within 60 days of first clinic appointment demonstrated by estrogen receptor (ER) 0% (absence or very low presence of estrogen uptake), progesterone receptor (PR) 0% (absence or very low presence of progesterone uptake), and HER2 negative (immunohistochemistry [IHC] score of 0 or 1 or fluorescence in situ hybridization [FISH] non-amplified score 2.0 or less) Tumor size >= 1 cm (chemotherapy is not recommended for tumors < 1 cm) Breast cancer stage I, II, or III Self-identify as of African descent (African American, African, Black, Afro-Caribbean, etc.) Completion of treatment planning team meeting and receipt of treatment at MD Anderson or local oncologist under the guidance of MD Anderson medical oncologist; no time window for treatment completion Ability to read, write, and speak in English, and provide consent  Exclusion Criteria:  Patients with previous history of breast cancer diagnosis Patients with newly diagnosed bilateral breast cancer Patients with psychiatric disorders that exceed moderate severity documented within patient medical record